Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes

This is an interventional health services research trial for Diabetes Mellitus, Type 2 Read More

Inclusion Criteria:

Patient

• Patients with T2DM defined as ≥2 outpatient diagnoses of T2DM in any position on separate days; OR ≥1 inpatient diagnosis T2DM in any position; OR ≥1 outpatient diagnosis in any position AND ≥1 medication claim for T2DM
• ≥1 diagnosis code for ASCVD (coronary artery disease diagnoses or procedures, cerebrovascular disease, peripheral artery disease of atherosclerotic origin) on any claim type in any position within the 24-month period prior to identification
• Enrolled in a Humana Medicare Advantage Prescription Drug plan with ≥12 months pre-identification continuous enrollment (no more than a 31 day gap) as of the identification date and currently enrolled as of the identification date
• Age 18-85 years at time of identification
• Patients residing in Kentucky (KY), West Virginia (WV), Pennsylvania (PA), and 6 counties in south New Jersey (NJ) (Burlington, Camden, Cumberland, Gloucester, Mercer, Salem) (United States)

Provider

• Primary care providers of the identified patients

Exclusion Criteria:

Patients

• ≥1 diagnosis or procedure code for end-stage kidney disease, renal transplant, dialysis or kidney failure
• Any hospice or long-term care residence
• ≥1 code for pregnancy/childbirth
• Patients with any use of SGLT2i or GLP-1 RA medications in the pre-identification period
• Patients without an attributed primary care provider
• Patients on do not contact lists
• Patients without valid addresses and telephone numbers
• Patients with ≥1 diagnosis for type 1 diabetes pre-identification

Primary care providers

• Providers on do not contact lists
• Providers without valid fax/mailing address and phone number
• Providers with <3 or >50 eligible patients